SLDB

Solid Biosciences (SLDB)

Solid Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SLDB

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/20	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SLDB	Solid Biosciences Inc
2024/05/15	21 : 26	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:SLDB	Solid Biosciences Inc
2024/05/15	20 : 52	GlobeNewswire Inc.	Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results	NASDAQ:SLDB	Solid Biosciences Inc
2024/05/15	20 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SLDB	Solid Biosciences Inc
2024/05/07	20 : 00	GlobeNewswire Inc.	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting	NASDAQ:SLDB	Solid Biosciences Inc
2024/05/07	07 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/05/03	05 : 05	GlobeNewswire Inc.	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:SLDB	Solid Biosciences Inc
2024/04/04	05 : 05	GlobeNewswire Inc.	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:SLDB	Solid Biosciences Inc
2024/04/01	20 : 45	GlobeNewswire Inc.	Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	NASDAQ:SLDB	Solid Biosciences Inc
2024/03/27	20 : 00	GlobeNewswire Inc.	Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	NASDAQ:SLDB	Solid Biosciences Inc
2024/03/13	20 : 44	GlobeNewswire Inc.	Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	NASDAQ:SLDB	Solid Biosciences Inc
2024/03/07	21 : 00	GlobeNewswire Inc.	Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	NASDAQ:SLDB	Solid Biosciences Inc
2024/03/06	22 : 00	GlobeNewswire Inc.	Solid Biosciences to Participate at Upcoming Investor Conferences	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/17	02 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/17	01 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/17	01 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/17	01 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/17	01 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/17	00 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/02/09	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/31	07 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/31	06 : 09	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/20	09 : 23	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/16	22 : 50	Dow Jones News	Solid Biosciences Gets Orphan Drug Designation for SGT-003	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/16	22 : 00	GlobeNewswire Inc.	Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/13	07 : 05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/12	07 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/11	06 : 31	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/08	21 : 24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLDB	Solid Biosciences Inc
2024/01/08	21 : 09	GlobeNewswire Inc.	Solid Biosciences Announces $109 Million Private Placement	NASDAQ:SLDB	Solid Biosciences Inc